PMID- 37440994
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 1178-7031 (Print)
IS  - 1178-7031 (Electronic)
IS  - 1178-7031 (Linking)
VI  - 16
DP  - 2023
TI  - Efferocytosis: An Emerging Therapeutic Strategy for Type 2 Diabetes Mellitus and 
      Diabetes Complications.
PG  - 2801-2815
LID - 10.2147/JIR.S418334 [doi]
AB  - Increasing evidence indicates that chronic, low-grade inflammation is a 
      significant contributor to the fundamental pathogenesis of type 2 diabetes 
      mellitus (T2DM). Efferocytosis, an effective way to eliminate apoptotic cells 
      (ACs), plays a critical role in inflammation resolution. Massive accumulation of 
      ACs and the proliferation of persistent inflammation caused by defective 
      efferocytosis have been proven to be closely associated with pancreatic islet beta 
      cell destruction, adipose tissue inflammation, skeletal muscle dysfunction, and 
      liver metabolism abnormalities, which together are considered the most 
      fundamental pathological mechanism underlying T2DM. Therefore, here we outline 
      the association between the molecular mechanisms of efferocytosis in glucose 
      homeostasis, T2DM, and its complications, and we analyzed the present constraints 
      and potential future prospects for therapeutic targets in T2DM and its 
      complications.
CI  - (c) 2023 Liu et al.
FAU - Liu, Xun
AU  - Liu X
AUID- ORCID: 0009-0006-2671-0459
AD  - Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic 
      of China.
FAU - Liu, Hua
AU  - Liu H
AD  - Southern Theater General Hospital of the Chinese People's Liberation Army, 
      Guangzhou, Guangdong, 510010, People's Republic of China.
FAU - Deng, Yihui
AU  - Deng Y
AD  - Hunan University of Chinese Medicine, Changsha, Hunan, 410208, People's Republic 
      of China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230707
PL  - New Zealand
TA  - J Inflamm Res
JT  - Journal of inflammation research
JID - 101512684
PMC - PMC10335275
OTO - NOTNLM
OT  - apoptosis
OT  - diabetes complications
OT  - efferocytosis
OT  - inflammation
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflicts of interest in this work.
EDAT- 2023/07/13 19:14
MHDA- 2023/07/13 19:15
PMCR- 2023/07/07
CRDT- 2023/07/13 15:18
PHST- 2023/04/22 00:00 [received]
PHST- 2023/06/24 00:00 [accepted]
PHST- 2023/07/13 19:15 [medline]
PHST- 2023/07/13 19:14 [pubmed]
PHST- 2023/07/13 15:18 [entrez]
PHST- 2023/07/07 00:00 [pmc-release]
AID - 418334 [pii]
AID - 10.2147/JIR.S418334 [doi]
PST - epublish
SO  - J Inflamm Res. 2023 Jul 7;16:2801-2815. doi: 10.2147/JIR.S418334. eCollection 
      2023.